Clinical, hormonal and magnetic resonance imaging (MRI) predictors of transsphenoidal surgery outcome in acromegaly

European Journal of Endocrinology

Volumn 150, Issue 6, 2004, Pages 763-771

  Bourdelot, Aline ^a   Coste, Joel ^a   Hazebroucq, Vincent ^a   Gaillard, Stephan ^b   Cazabat, Laure ^a,c   Bertagna, Xavier ^a,c   Bertherat, Jérôme ^a,c  

^a Hôpital Cochin ^*  (France)

^b FOCH HOSPITAL   (France)

^c INSTITUT COCHIN   (France)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; GROWTH HORMONE; SOMATOMEDIN C; HUMAN GROWTH HORMONE;

ACROMEGALY; ADULT; ARTICLE; CLINICAL FEATURE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; FEMALE; HORMONE DETERMINATION; HUMAN; HYPOPHYSIS; HYPOPHYSIS ADENOMA; LIQUORRHEA; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MEDICAL ASSESSMENT; NEURORADIOLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; ORAL GLUCOSE TOLERANCE TEST; POSTOPERATIVE HEMORRHAGE; POSTOPERATIVE PERIOD; PREDICTION; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROBABILITY; REMISSION; RETROSPECTIVE STUDY; TRANSSPHENOIDAL HYPOPHYSECTOMY; TREATMENT OUTCOME; TUMOR VOLUME; ADENOMA; ANALYSIS OF VARIANCE; BLOOD; GLUCOSE TOLERANCE TEST; HYPOPHYSIS TUMOR; MIDDLE AGED; PATHOLOGY; SECRETION; STATISTICAL MODEL;

ACROMEGALY; ADENOMA; ADULT; ANALYSIS OF VARIANCE; GLUCOSE TOLERANCE TEST; HUMAN GROWTH HORMONE; HUMANS; INSULIN-LIKE GROWTH FACTOR I; LOGISTIC MODELS; MAGNETIC RESONANCE IMAGING; MIDDLE AGED; PITUITARY NEOPLASMS; REMISSION INDUCTION; TREATMENT OUTCOME;

EID: 3242717037     PISSN: 08044643     EISSN: None     Source Type: Journal    
DOI: 10.1530/eje.0.1500763     Document Type: Article

References (42)

1. Laws ER Jr & Thapar K. Pituitary surgery. Endocrinology and Metabolism Clinics of North America 1999 28 119-131.
2. Wilson CB. Surgical management of pituitary tumors. Journal of Clinical Endocrinology and Metabolism 1997 82 2381-2385.
3. Melmed S, Jackson I, Kleinberg D & Klibanski A. Current treatment guidelines for acromegaly. Journal of Clinical Endocrinology and Metabolism 1998 83 2646-2652.
4. Hardy J. Transsphenoidal hypophysectomy. Journal of Neurosurgery 1971 34 582-594.
5. Giustina A, Barkan A, Casanueva FF, Cavagnini F, Frohman L, Ho K, Veldhuis J, Wass J, Von Werder K & Melmed S. Criteria for cure of acromegaly: a consensus statement. Journal of Clinical Endocrinology and Metabolism 2000 85 526-529.
6. Biermasz NR, van Dulken H & Roelfsema F. Ten-year follow-up results of transsphenoidal microsurgery in acromegaly. Journal of Clinical Endocrinology and Metabolism 2000 85 4596-4602.
7. Kreutzer J, Vance ML, Lopes MB & Laws ER Jr. Surgical management of GH-secreting pituitary adenomas: an outcome study using modern remission criteria. Journal of Clinical Endocrinology and Metabolism 2001 86 4072-4077.
8. Freda PU, Wardlaw SL & Post KD. Long-term endocrinological follow-up evaluation in 115 patients who underwent transsphenoidal surgery for acromegaly. Journal of Neurosurgery 1998 89 353-358.
9. Holdaway IM & Rajasoorya C. Epidemiology of acromegaly. Pituitary 1999 2 29-41.
10. Bates AS, Van't Hoff W, Jones JM & Clayton RN. An audit of outcome of treatment in acromegaly. Quarterly Journal of Medicine 1993 86 293-299.
11. Rajasoorya C, Holdaway IM, Wrightson P, Scott DJ & Ibbertson HK. Determinants of clinical outcome and survival in acromegaly. Clinical Endocrinology 1994 41 95-102.
12. Abosch A, Tyrrell JB, Lamborn KR, Hannegan LT, Applebury CB & Wilson CB. Transsphenoidal microsurgery for growth hormone-secreting pituitary adenomas: initial outcome and long-term results, Journal of Clinical Endocrinology and Metabolism 1998 83 3411-3418.
13. Orme SM, McNally RJ, Cartwright RA & Belchetz PE. Mortality and cancer incidence in acromegaly: a retrospective cohort study. United Kingdom Acromegaly Study Group. Journal of Clinical Endocrinology and Metabolism 1998 83 2730-2734.
14. Swearingen B, Barker FG 2nd, Katznelson L, Biller BM, Grinspoon S, Klibanski A, Moayeri N, Black PM & Zervas NT. Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly. Journal of Clinical Endocrinology and Metabolism 1998 83 3419-3426.
15. Barrande G, Pittino-Lungo M, Coste J, Ponvert D, Bertagna X, Luton JP & Bertherat J. Hormonal and metabolic effects of radio-therapy in acromegaly: long-term results in 128 patients followed in a single center. Journal of Clinical Endocrinology and Metabolism 2000 85 3779-3785.
16. Biermasz NR, van Dulken H & Roelfsema F. Long-term follow-up results of postoperative radiotherapy in 36 patients with acromegaly. Journal of Clinical Endocrinology and Metabolism 2000 85 2476-2482.
17. Caron P, Morange-Ramos I, Cogne M & Jaquet P. Three-year follow-up of acromegalic patients treated with intramuscular slow-release lanreotide. Journal of Clinical Endocrinology and Metabolism 1997 82 18-22.
18. Newman CB, Melmed S, Snyder PJ, Young WF, Boyajy LD, Levy R, Stewart WN, Klibanski A, Molitch ME & Gagel RF. Safety and efficacy of long-term octreotide therapy of acromegaly: results of a multicenter trial in 103 patients - a clinical research center study. Journal of Clinical Endocrinology and Metabolism 1995 80 2768-2775.
19. Stewart PM, Kane KF, Stewart SE, Lancranjan I & Sheppard MC. Depot long-acting somatostatin analog (Sandostatin-LAR) is an effective treatment for acromegaly. Journal of Clinical Endocrinology and Metabolism 1995 80 3267-3272.
20. Trainer PJ, Drake WM, Katznelson L, Freda PU, Herman-Bonert V, van der Lely AJ, Dimaraki EV, Stewart PM, Friend KE, Vance ML, Besser GM, Scarlett JA, Thorner MO, Parkinson C, Klibanski A, Powell JS, Barkan AL, Sheppard MC, Malsonado M, Rose DR, Clemmons DR, Johannsson G, Bengtsson BA, Stavrou S, Kleinberg DL, Cook DM, Phillips LS, Bidlingmaier M, Strasburger CJ, Hackett S, Zib K, Bennett WF & Davis RJ. Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. New England Journal of Medicine 2000 342 1171-1177.
21. Baldelli R, Colao A, Razzore P, Jaffrain-Rea ML, Marzullo P, Ciccarelli E, Ferretti E, Ferone D, Gaia D, Camanni F, Lombardi G & Tamburrano G. Two-year follow-up of acromegalic patients treated with slow release lanreotide (30mg). Journal of Clinical Endocrinology and Metabolism 2000 85 4099-4103.
22. Flogstad AK, Halse J, Bakke S, Lancranjan I, Marbach P, Bruns C & Jervell J. Sandostatin LAR in acromegalic patients: long-term treatment. Journal of Clinical Endocrinology and Metabolism 1997 82 23-28.
23. Newman CB, Melmed S, George A, Torigian D, Duhaney M, Snyder P, Young W, Klibanski A, Molitch ME, Gagel R, Sheeler L, Cook D, Malarkey W, Jackson I, Vance ML, Barkan A, Frohman L & Kleinberg DL. Octreotide as primary therapy for acromegaly. Journal of Clinical Endocrinology and Metabolism 1998 83 3034-3040.
24. Amato G, Mazziotti G, Rotondi M, Iorio S, Doga M, Sorvillo F, Manganella G, Di Salle F, Giustina A & Carella C. Long-term effects of lanreotide SR and octreotide LAR on tumour shrinkage and GH hypersecretion in patients with previously untreated acromegaly. Clinical Endocrinology (Oxford) 2002 56 65-71.
25. Atkin SL, Atkinson AB, Bouloux PM, Hanna F, Harris PE, James RA, McConnell M, Roberts GA, Scanlon MF, Stewart PM, Teasdale E, Turner HE, Wass JA & Wardlaw JM. Primary medical therapy for acromegaly: an open, prospective, multicenter study of the effects of subcutaneous and intramuscular slow-release octreotide on growth hormone, insulin-like growth factor-I, and tumor size. Journal of Clinical Endocrinology and Metabolism 2002 87 4554-4563.
26. van der Lely AJ, Hutson RK, Trainer PJ, Besser GM, Barkan AL, Katznelson L et al. Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist. Lancet 2001 358 1754-1759.
27. Sheaves R, Jenkins P, Blackburn P, Huneidi AH, Afshar F, Medbak S, Grossman AB, Besser GM & Wass JA. Outcome of transsphenoidal surgery for acromegaly using strict criteria for surgical cure. Clinical Endocrinology (Oxford) 1996 45 407-413.
28. Osman IA, James RA, Chatterjee S, Mathias D & Kendall-Taylor P. Factors determining the long-term outcome of surgery for acromegaly. Quarterly Journal of Medicine 1994 87 617-623.
29. Kaltsas GA, Isidori AM, Florakis D, Trainer PJ, Camacho-Hubner C, Afshar F, Sabin I, Jenkins JP, Chew SL, Monson JP, Besser GM & Grossman AB. Predictors of the outcome of surgical treatment in acromegaly and the value of the mean growth hormone day curve in assessing postoperative disease activity. Journal of Clinical Endocrinology and Metabolism 2001 86 1645-1652.
30. Ahmed S, Elsheikh M, Stratton IM, Page RC, Adams CB & Wass JA. Outcome of transphenoidal surgery for acromegaly and its relationship to surgical experience. Clinical Endocrinology (Oxford) 1999 50 561-567.
31. Lissett CA, Peacey SR, Laing I, Tetlow L, Davis JR & Shalet SM. The outcome of surgery for acromegaly: the need for a specialist pituitary surgeon for all types of growth hormone (GH) secreting adenoma. Clinical Endocrinology (Oxford) 1998 49 653-657.
32. Elster AD. Modern imaging of the pituitary. Radiology 1993 187 1-14.
33. Marro B, Zouaoui A, Sahel M, Crozat N, Gerber S & Sourour N. MRI of pituitary adenomas in acromegaly. Neuroradiology 1997 39 394-399.
34. Cottier JP, Destrieux C, Vinikoff-Sonier C, Jan M & Herbreteau D. MRI diagnosis of cavernous sinus invasion by pituitary adenomas. Annales d'Endocrinologie (Paris) 2001 61 269-274.
35. Knosp E, Steiner E, Kitz K & Matula C. Pituitary adenomas with invasion of the cavernous sinus space: a magnetic resonance imaging classification compared with surgical findings. Neurosurgery 1993 33 610-617.
36. Rieger A, Rainov NG, Ebel H, Sanchin L, Shibib K, Helfrich C, Hoffmann O & Burkert W. Factors predicting pituitary adenoma invasiveness in acromegalic patients. Neurosurgical Review 1997 20 182-187.
37. Jenkins D, O'Brien I, Johnson A, Shakespear R, Sheppard MC & Stewart PM. The Birmingham pituitary database: auditing the outcome of the treatment of acromegaly. Clinical Endocrinology 1995 43 517-522.
38. Serri O, Somma M, Comtois R, Rasio E, Beauregard H, Jilwan N & Hardy J. Acromegaly: biochemical assessment of cure after long-term follow-up of transsphenoidal selective adenomectomy. Journal of Clinical Endocrinology and Metabolism 1985 61 1185-1189.
39. Tindall GT, Oyesiku NM, Watts NB, Clark RV, Christy JH & Adams DA. Transsphenoidal adenomectomy for growth hormone-secreting pituitary adenomas in acromegaly: outcome analysis and determinants of failure. Journal of Neurosurgery 1993 78 205-215.
40. Ross DA & Wilson CB. Results of transsphenoidal microsurgery for growth hormone-secreting pituitary adenoma in a series of 214 patients. Journal of Neurosurgery 1988 68 854-867.
41. Rieu M, Girard F, Bricaire H & Binoux M. The importance of insulin-like growth factor (somatomedin) measurements in the diagnosis and surveillance of acromegaly. Journal of Clinical Endocrinology and Metabolism 1982 55 147-153.
42. Ho KY & Weissberger AJ. Characterization of 24-hour growth hormone secretion in acromegaly: implications for diagnosis and therapy. Clinical Endocrinology 1994 41 75-83.